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Abstract
Background: Myocardial native T1 measurements are likely influenced by intramyocardial blood. Since blood T1 is
both variable and longer compared to myocardial T1, this will degrade the precision of myocardial T1 measurements.
Precision could be improved by correction, but the amount of correction and the optimal blood T1 variables to correct
with are unknown. We hypothesized that an appropriate correction would reduce the standard deviation (SD) of native
myocardial T1.
Methods: Consecutive patients (n = 400) referred for CMR with known or suspected heart disease were split into a
derivation cohort for model construction (n = 200, age 51 ± 18 years, 50% male) and a validation cohort for assessing
model performance (n = 200, age 48 ± 17 years, 50% male). Exclusion criteria included focal septal abnormalities. A
Modified Look-Locker inversion recovery sequence (MOLLI, 1.5 T Siemens Aera) was used to acquire T1 and T1* maps. T1
and T1* maps were used to measure native myocardial T1, and blood T1 and T1*. A multivariate linear regression
correction model was implemented using blood measurement of R1 (1/T1), R1* (1/T1*) or hematocrit. The correction
model from the derivation cohort was applied to the validation cohort, and assessed for reduction in variability with the
F-test.
Results: Blood [LV + RV] mean R1, mean R1* and hematocrit correlated with myocardial T1 (Pearson’s r, range 0.37
to 0.45, p < 0.05 for all) in both the derivation and validation cohorts respectively, suggesting that myocardial T1
measurements are influenced by intramyocardial blood. Mean myocardial native T1 did not differ between the
derivation and validation cohorts (1030 ± 42.6 ms and 1023 ± 45.2 ms respectively, p = 0.07). In the derivation cohort,
correction using blood mean R1 and mean R1* yielded a decrease in myocardial T1 SD (45.2 ms to 36.6 ms, p = 0.03).
When the model from the derivation cohort was applied to the validation cohort, the SD reduction was maintained
(39.3 ms, p = 0.049). This 13% reduction in measurement variability leads to a 23% reduction in sample size to detect a
50 ms difference in native myocardial T1.
Conclusions: Correcting native myocardial T1 for R1 and R1* of blood improves the precision of myocardial
T1 measurement by ~13%, and could consequently improve disease detection and reduce sample size needs
for clinical research.
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Background
Parametric pixel-wise mapping has been developed to
quantitatively measure and image the longitudinal mag-
netic relaxation time (T1) [1]. Native myocardial T1 map-
ping has shown diagnostic promise for differentiating
healthy myocardium from various pathologies including
acute myocardial infarction [2], myocarditis [3, 4], amyloid-
osis [5], edema [6], Anderson-Fabry disease [7] and other
non-ischemic diseases [8, 9]. Reference values for native
myocardial T1 in ischemic and several non-ischemic heart
diseases have been reported, with cutoff values for age, and
sex [10], which suggests that native myocardial T1 map-
ping is a robust diagnostic tool for myocardial tissue
characterization in clinical use [5, 11, 12].
However, the normal myocardial blood volume (MBV)
averages approximately 6% of the myocardium [13, 14].
The T1 value of blood is higher than the T1 value of the
myocardium, thus the T1 value of the myocardium is ex-
pected to be influenced by both the T1 value, and the
amount of blood in the myocardium. The partial volume
effect describes the concept that a single voxel may con-
tain tissue of different characteristics, whereas the pixel
value for that voxel will represent a combination of these
contents [15]. Furthermore, the myocardial T1 values
reflect a volume of tissue consisting of myocytes, extra-
cellular connective tissue, nerves, blood vessels and the
blood therein [16, 17]. Therefore, myocardial T1 values
should relate to the summed composition of the tissue,
including the microcirculation. The T1 values of blood
have been shown to vary due to a number of factors like
hematocrit [18], sex [10], age [19], and oxygen pressure
[18, 20] and variations in these factors may influence the
interpretation of myocardial T1 values, and obscure the
true T1 value of the myocardium.
Approaches for correcting for myocardial blood vol-
ume have been reported [21, 22]. Reiter et al. showed
that myocardial T1 differences by age and sex were elim-
inated when corrected for T1 measured in the blood
pool of the left ventricle (LV) [22]. This correction could
therefore decrease the variability of native myocardial
T1 between patients, thus improving the clinical accur-
acy. Therefore, the purpose of this study was to identify
a blood correction model, with cardiovascular magnetic
resonance (CMR) available measurements, which in a
future implementation could allow automated inline
blood-corrected T1 maps, and validate this model in a
separate clinical cohort. A technical aspect of an auto-
mated method for blood correction is blood segmenta-
tion. Therefore, the mean blood T1 values of both
ventricles (LV and right ventricle (RV)) were acquired.
Blood T1* measurements were also investigated. Since
there is no reference method for measuring myocardial
T1 values, we hypothesized that blood correction could
reduce the variability in native myocardial T1 values in a
clinical population, measured as a decrease in standard
deviation (SD).
Methods
Study population
Consecutive patients referred for diagnostic CMR for
known or suspected heart disease at Karolinska University
Hospital, Stockholm, Sweden, were retrospectively en-
rolled between 2014-01-02 and 2015-08-07. Inclusion was
terminated when a total of 200 males and 200 females
were included, respectively. A total of 543 patients were
assessed for eligibility. Exclusion criteria included focal
septal myocardial pathologies, cardiac shunts, poor image
quality or presence of cardiac tumors, see Fig. 1. Included
patients were randomly assigned to either the derivation
or the validation cohort. Hematocrit was determined by
venous blood sampling prior to CMR, as a part of the clin-
ical routine. Venous blood was drawn with a syringe from
an intravenous access cannula, and analyzed by an iSTAT
Handheld Blood Analyzer®, using a CHEM8+ cartridge
(Abbot Point of Care, Princeton, USA). The study was ap-
proved by the local research ethics committee, and all pa-
tients provided written informed consent.
Healthy volunteers (n = 77, mean age 49 ± 14 years, 49%
males) were prospectively recruited between April 2014
and July 2015 through local advertising. None of the vol-
unteers had any cardiovascular disease or diabetes. Five
were on statins and one was on aspirin for primary
prevention. All volunteers had a normal 12-lead ECG and
all scans were reported as normal by experienced Level 3
CMR cardiologists. Imaging was performed on a 1.5 T
MR scanner (Magnetom Avanto, Siemens, Erlangen,
Germany) and a 32-channel cardiac phased array receiver
coil was used. The imaging protocol included cines, native
T1 mapping, T2 mapping, Late Gadolinium Enhancement
Fig. 1 Patient selection
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(LGE) and post-contrast T1 mapping. For this study, only
the native T1 and T1* maps were analysed. Whole blood
for venous hematocrit was drawn in all subjects by
venipuncture and analyzed as routine clinical samples
using a Sysmex XE-2100 hematology analyzer (Sysmex,
Kobe, Japan) [23].
Image acquisition
All patient CMR scans were conducted on a 1.5 T scan-
ner (Siemens Aera, Erlangen, Germany) with a phased-
array 18-channel body matrix coil together with a spine
matrix coil. All patients were examined in the supine
position. CMR scans assessing LV function used retro-
spectively electrocardiographically gated balanced
steady-state free precession (bSSFP) cine imaging cover-
ing the entire LV. Typical imaging parameters included
flip angle = 61°, voxel size = 2.0x2.0x8.0 mm3, TR/TE =
37.05/1.19 ms, matrix size = 143x256 and field of
view (FoV) 303x360 mm2.
T1 maps were acquired using an electrocardiographi-
cally gated Modified Look-Locker inversion recovery
(MOLLI) sequence [24] with a 5(3)3 sampling scheme
(Siemens WIP 1041). T1 maps were reconstructed using
inline motion correction [25], and reconstruction output
included a T1 error map, a T1* map and a T1 map.
Typical image acquisition parameters were: steady-state
free precession single-shot read out with a trigger delay
to coincide with end-diastole, flip angle = 35°, matrix
size = 144x256, TE = 2.6 ms, TR = 278 ms, FoV =
270x360 mm2, parallel acquisition technique (PAT) fac-
tor 2, number of inversion 2, data window duration
163 ms. Operators were allowed to perform standard
cardiac planning adjusting for patient size, rendering a
range of phase encoding lines 136–158, and FoV 241–
384 x 300–410 mm2.
The healthy volunteers were imaged using a 5s(3s)3s
MOLLI protocol. The acquisition parameters were: pixel
bandwidth 977 Hz/pixel; echo time = 1.1 ms; flip angle =
35°; matrix size = 256x144; slice thickness = 6 mm.
Motion correction and a non-linear least-square curve
fitting were performed with the set of images acquired at
different inversion times to generate a pixel-wise T1
map and T1* map.
Image analysis
LV volumes, ejection fraction (EF) and myocardial mass
were quantified using the SyngoVia Software, VA30
(Siemens, Erlangen, Germany). Body surface area (BSA)
was calculated with the Du Bois formula [26]. Volumet-
ric measurements and myocardial mass were indexed to
BSA. Native myocardial T1 values were measured by
one observer by manually delineating a region of interest
(ROI), conservatively placed, to avoid partial volume
effects, in the mid-mural third of the septum of a mid-
ventricular short-axis T1 map using a clinical work
station (IDS7, Sectra, Linköping, Sweden). Blood T1 and
T1* values were measured in the blood pool of both
ventricles as the mean value of two manually delineated
ROIs in the corresponding mid-ventricular short-axis T1
and T1* maps. The ROIs were delineated as large as
possible without including papillary muscle and trabecu-
lae, see Fig. 2. Myocardial wall thickness was measured
in the septum in the corresponding bSSFP cine short-
axis slice, in end-diastole. Mean blood T1 and T1*
values were calculated as the average of blood T1 and
T1* from the RV and the LV, and converted to the T1 re-
laxation rate (R1 = 1/T1). This yielded mean blood R1
and mean blood R1*. R1, as opposed to T1, is linearly re-
lated to the concentration of differing T1 species such as
contrast agent or blood in the setting of the current
study.
A linear correlation between septal myocardial T1 and
blood measurements was assumed. T1 was corrected
using the equation, Equation 1:
T1corrected ¼ T1uncorrected þ constant⋅ Xmean−Xpatient
 
where X is the blood measurement of mean R1, mean
Fig. 2 Short-axis T1 and T1* maps. The figure shows regions of interest (ROI) drawn for native myocardial T1 values of the mid-mural septum, LV
blood pool T1 and T1* values, and RV blood pool T1 and T1* values
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R1* or hematocrit, mean is the mean for the patient co-
hort, and the constant was calculated as the slopes of
linear regression between myocardial T1 and the blood
measurements.
The T1 maps from the healthy volunteers were analysed
using CVI42 software (Circle Cardiovascular Imaging
Inc.,Version 5.1.2 [303], Calgary, Canada) by one observer.
Global myocardial T1 values were acquired by carefully
delineating the endo- and epicardial borders and eroding
10% to acquire the middle 80% of the myocardium. ROIs
were drawn in the LV and RV blood pools of the mid-
ventricular short-axis slice of the native T1 and T1* maps,
and care was taken to avoid papillary muscles.
Statistical analysis
Continuous variables were reported as mean and SD.
Statistical analysis was performed using Microsoft Excel
(Microsoft, Redmond, Washington, USA), and statistical
testing was performed using Statistical Product and Ser-
vice Solutions® (IBM SPSS Statistics 23, IBM, New York,
USA). Statistical significance was defined as p < 0.05.
Multivariate linear regression was performed for slopes
used for correction of native myocardial T1 for combinations
of blood characteristics in the derivation cohort. The blood
correction model from the derivation cohort was applied to
the validation cohort, and the healthy volunteers respectively.
The relationships between corrected and uncorrected native
myocardial T1 values were investigated by the SD of the
mean native myocardial T1, and evaluated for differences
with the F-test. Mean values were compared by using the
paired or unpaired t-test as appropriate in normally distrib-
uted data, and Mann–Whitney U-test in data with non-
normal distribution. Sample size calculations were performed
using Microsoft Excel.
Results
Study population
Baseline characteristics of the derivation and validation
cohorts are shown in Table 1. Mean uncorrected native
myocardial T1 was 1030 ± 42.6 ms in the derivation co-
hort, 1023 ± 45.2 ms, (p = 0.07) in the validation cohort,
and 1027 ± 37.5 ms in the healthy volunteers. Hematocrit
range for all 400 patients was 25 to 57%. There was no
difference in characteristics between the derivation and
validation cohorts, except for LV stroke volume (SV) and
indexed LVSV (LVSVI), which was lower in the derivation
cohort, albeit with a small magnitude of difference. There
was no difference in characteristics between the females in
Table 1 Baseline characteristics of the derivation and validation cohorts
Characteristic Derivation cohort (n = 200)a Validation cohort (n = 200)a p-value
Age (years) 51 ± 18 48 ± 17 0.14
Female sex, n (%) 100 (50%) 100 (50%) 1.0
Height (cm) 173 ± 14 174 ± 10 0.44
Weight (kg) 77 ± 16 78 ± 18 0.79
BSA (m2) 1.9 ± 0.3 1.9 ± 0.2 0.95
LVEDV (ml) 180 ± 63 183 ± 63 0.56
LVEDVI (ml/m2) 94 ± 29 95 ± 32 0.61
LVESV (ml) 91 ± 57 88 ± 57 0.81
LVESVI (ml/m2) 47 ± 28 46 ± 29 0.95
LVSV (ml) 89 ± 27 95 ± 25 0.02*
LVSVI (ml/m2) 47 ± 14 50 ± 11 0.01*
LVEF (%) 52 ± 12 54 ± 11 0.06
LVM (g) 138 ± 46 137 ± 53 0.75
LVMI (g/m2) 71 ± 19 72 ± 23 0.95
ECV (%) 28 ± 4 28 ± 4 0.51
Hematocrit (%) 40 ± 4 40 ± 5 0.71
Septal wall thickness (mm) 10 ± 2 10 ± 2 0.45
Myocardial T1 (ms) 1030 ± 43 1023 ± 45 0.07
Mean blood R1 (ms−1) 0.00064 ± 0.00004 0.00064 ± 0.00004 0.49
Mean blood R1* (ms−1) 0.00061 ± 0.00005 0.00061 ± 0.00005 0.98
Characteristics are given as means ± standard deviations, or percentages as appropriate. p-values refer to comparison of mean values between derivation and
validation cohort. *marks significant result. aData missing for LV volumes, EF and mass (n = 2), and ECV (n = 4) in the derivation cohort. Data missing for ECV (n = 2)
in the validation cohort
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the validation and derivation cohorts shown in Table 2.
There was no difference between the males in the deriv-
ation and validation cohorts, except for LVSV and LVSVI,
Table 3.
Myocardial T1 correlation
All the blood measurements correlated with uncorrected
native myocardial T1 in both the derivation and validation
cohorts, see Table 4. Myocardial wall thickness was not
correlated with native myocardial T1, and was therefore
not included in the multivariate analysis. Hematocrit had
the weakest correlation in both the derivation and valid-
ation cohort, respectively. Mean R1 and mean R1* had the
same correlation in the derivation cohort, whereas mean
R1 alone had the best correlation in the validation cohort.
Myocardial T1 blood correction
Multivariate linear regression in the derivation cohort
showed that the best correction model was a combin-
ation of mean R1 and mean R1* (R2 0.26, p < 0.001), see
Table 4. The constants from the regression model were
used to correct native myocardial T1 values according to
Equation 1. The blood correction model for mean R1
and mean R1* decreased the SD of myocardial T1 to
36.6 ms (p = 0.03) in the derivation cohort, see Fig. 3.
The model also decreased the SD of myocardial T1
values in the validation cohort to 39.3 ms (p = 0.049), see
Fig. 3. Mean uncorrected myocardial T1 in the deriv-
ation cohort was 1015 ± 38.6 ms for males and 1046 ±
41.1 ms for females (p < 0.001). The difference in mean
myocardial T1 between males and females was elimi-
nated by blood correction in the derivation cohort
(1025 ± 33.3 ms vs 1035 ± 39.2 ms, p = 0.09), see Fig. 4.
In the validation cohort, the mean uncorrected myocar-
dial T1 was 1005 ± 38.6 ms for males and 1040 ±
37.0 ms for females (p < 0.001). The difference in mean
myocardial T1 between males and females was reduced,
but remained significant following blood correction, al-
beit by a small magnitude (1015 ± 40 ms vs 1028 ±
37.6 ms, p = 0.02), see Fig. 5. The range in myocardial
T1 values in the derivation cohort decreased with 25%
following blood correction (908–1183 ms vs 941–
1146 ms).
Myocardial blood correction in healthy volunteers
The SD of uncorrected myocardial T1 measurements of
the healthy volunteers was 37.5 ms. The blood correc-
tion model for mean R1 and mean R1* did not decrease
the SD (36.7 ms, p = 0.85). The mean uncorrected myo-
cardial T1 in the healthy volunteers was 1012 ± 30.4 ms
for males and 1042 ± 38.0 ms for females (p < 0.001).
The difference in mean myocardial T1 between males
Table 2 Baseline characteristics of the females in the derivation and validation cohorts
Characteristic, females (n = 200) Derivation cohort (n = 100)a Validation cohort (n = 100)a p-value
Age (years) 52 ± 18 49 ± 17 0.21
Female sex, n (%) 100 (100%) 100 (100%) 1.0
Height (cm) 165 ± 8 167 ± 7 0.17
Weight (kg) 69 ± 14 70 ± 16 0.89
BSA (m2) 1.8 ± 0.2 1.8 ± 0.2 0.77
LVEDV (ml) 157 ± 52 159 ± 49 0.48
LVEDVI (ml/m2) 89 ± 28 89 ± 26 0.47
LVESV (ml) 91 ± 57 88 ± 57 0.81
LVESVI (ml/m2) 47 ± 28 46 ± 29 0.95
LVSV (ml) 78 ± 21 83 ± 20 0.65
LVSVI (ml/m2) 45 ± 11 47 ± 11 0.16
LVEF (%) 53 ± 12 54 ± 11 0.44
LVM (g) 110 ± 26 112 ± 42 0.41
LVMI (g/m2) 62 ± 14 64 ± 22 0.49
ECV (%) 29 ± 4 29 ± 3 0.72
Hematocrit (%) 38 ± 4 38 ± 5 0.93
Septal wall thickness (mm) 9 ± 2 9 ± 3 0.45
Myocardial T1 (ms) 1046 ± 41 1040 ± 37 0.29
Mean blood R1 (ms−1) 0.00062 ± 0.00003 0.00062 ± 0.00003 0.58
Mean blood R1* (ms−1) 0.00059 ± 0.00004 0.00054 ± 0.00005 0.95
Characteristics are given as means ± standard deviations, or percentages as appropriate. p-values refer to comparison of mean values of derivation and validation
cohort. aData missing for LV volumes, EF and mass (n = 2), and ECV (n = 4) in the derivation cohort. Data missing for ECV (n = 2) in the validation cohort
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and females was eliminated by blood correction in
the healthy volunteers (1012 ± 33.7 ms vs 1023 ±
39.0 ms, p = 0.20).
Differences in native myocardial T1
To ascertain if the partial-volume effect or hematocrit
range contributed to the differences in native myocar-
dial T1, the patients with the highest and lowest
quartiles of wall thickness and hematocrit were
examined in the derivation and validation cohorts, re-
spectively. Patients with the thickest (>11.4 mm) and
thinnest (<8.4 mm) myocardium had no difference in
native myocardial T1 in the derivation cohort (1036 ±
44 ms vs 1028 ± 39 ms, p = 0.30). In the validation co-
hort, there was no difference in native myocardial T1
between patients with the thickest (>11.1 mm) and
thinnest (<8.5 mm) myocardium (1026 ± 46 ms vs
1023 ± 38 ms, p = 0.76).
Table 3 Baseline characteristics of the males in the derivation and validation cohorts
Characteristic, males (n = 200) Derivation cohort (n = 100) Validation cohort (n = 100) p-value
Age (years) 49 ± 18 47 ± 18 0.40
Female sex, n (%) 0 (0%) 0 (0%) 1.0
Height (cm) 181 ± 14 180 ± 8 0.81
Weight (kg) 86 ± 14 85 ± 16 0.84
BSA (m2) 2.0 ± 0.3 2.1 ± 0.2 0.77
LVEDV (ml) 204 ± 64 207 ± 68 0.67
LVEDVI (ml/m2) 99 ± 29 100 ± 36 0.96
LVESV (ml) 103 ± 62 101 ± 64 0.71
LVESVI (ml/m2) 50 ± 29 49 ± 34 0.56
LVSV (ml) 99 ± 27 106 ± 24 0.047*
LVSVI (ml/m2) 49 ± 16 52 ± 11 0.02*
LVEF (%) 51 ± 12 54 ± 11 0.06
LVM (g) 166 ± 45 162 ± 51 1.0
LVMI (g/m2) 80 ± 20 80 ± 21 0.78
ECV (%) 27 ± 3 27 ± 4 0.60
Hematocrit (%) 42 ± 4 43 ± 4 0.41
Septal wall thickness (mm) 11 ± 2 11 ± 2 0.58
Myocardial T1 (ms) 1015 ± 39 1005 ± 46 0.10
Mean blood R1 (ms−1) 0.00066 ± 0.00004 0.00066 ± 0.00003 0.57
Mean blood R1* (ms−1) 0.00063 ± 0.00004 0.00063 ± 0.00004 0.98
Characteristics are given as mean ± standard deviations, or percentages as appropriate. p-values refer to comparison of derivation and validation cohort. *marks
significant results
Table 4 Correlations and multivariate linear regression coefficients
Characteristic Univariate r Multivariate beta Multivariate beta, final model Global R2
Derivation cohort (n = 200) 0.26 (p < 0.001)
Hematocrit (%) −0.37 (p < 0.001) 0.00 (p = 0.98)
Mean blood R1 (ms-1) −0.45 (p < 0.001) −0.28 (p = 0.003) −0.28 (p = 0.001)
Mean blood R1* (ms-1) −0.45 (p < 0.001) −0.28 (p = 0.002) −0.28 (p = 0.001)
Septal wall thickness (mm) 0.07 (p = 0.33) - -
Validation cohort (n = 200)
Hematocrit (%) −0.39 (p < 0.001)
Mean blood R1 (ms-1) −0.49 (p < 0.001)
Mean blood R1* (ms-1) −0.44 (p < 0.001)
Septal wall thickness (mm) 0.07 (p = 0.32) - -
All blood measurements correlated with myocardial T1, however hematocrit was not significant in multivariate regression analysis, and therefore not included in
the final model.
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Patients with the highest (>43%) and lowest (<37%)
hematocrit, differed significantly in myocardial T1 in
the derivation cohort (1017 ± 44 ms vs 1054 ± 43 ms, p
< 0.001). There was also a difference in myocardial T1
in the validation cohort, between patients with the
highest (>44%) and lowest (<37%) hematocrit (993 ±
41 ms vs 1046 ± 30 ms, p < 0.001). These differences
disappeared following blood correction, in both the
derivation cohort (1033 ± 36 ms vs 1034 ± 36 ms, p =
0.87) and in the validation cohort (1012 ± 43 ms vs
1020 ± 31 ms, p = 0.35).
The reduction in SD allows for detection of differences
with a smaller population in research studies. A reduc-
tion of 13% in SD reduces the sample size for identifying
a 50 ms difference in myocardial T1 from 26 patients to
20 patients (23% reduction in sample size).
Discussion
We have demonstrated that correcting for blood charac-
teristics decreases the variability of native myocardial T1
in a clinical population, and reduces gender differences
in healthy volunteers. Blood correction was achieved by
Fig. 3 Standard deviation of corrected and uncorrected myocardial T1. The figure shows the SD of mean myocardial T1 in ms for uncorrected
and blood corrected measurements, in the derivation cohort (black) and the validation cohort (white). The triangles denote reduction in
variability in percent. P-values denote F-test
Fig. 4 Mean myocardial T1 values for females compared to males,
derivation cohort. The figure displays the mean ± 95% limits of
agreement for females and males, prior to correction (black) and
after blood correction (white). The mean myocardial T1 values
differed between the sexes prior to blood correction, but the
differences were eliminated after correction. P-values denote paired
and unpaired t-test as appropriate
Fig. 5 Mean myocardial T1 values for females compared to males,
validation cohort. The figure displays the mean ± 95% limits of
agreement for females and males, prior to correction (black) and
after blood correction (white). The mean myocardial T1 values
differed significantly prior to blood correction, and the differences
were reduced, however not eliminated following correction. P-values
denote paired and unpaired t-test as appropriate
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using the average of LV and RV blood (mean blood R1
and mean blood R1*), resulting in a 13% reduction in
variability for native myocardial T1 measurements in the
validation cohort. Correction for hematocrit did not pro-
vide an incremental reduction in SD beyond image-
based blood characteristics. The use of the LV and RV
blood highlights the feasibility of implementing an auto-
matic blood pool mask [27], in order for inline recon-
struction of a blood corrected T1 map.
Importance of blood correction
There are several physiological factors that influence the
variation of blood T1 values, such as hematocrit [18],
sex [10], age [19] and oxygen pressure [18, 20]. Also,
technical aspects such as CMR magnetic field strength
[12, 28, 29], off-resonance effects [30], and adiabatic
inversion pulse imperfections [31] affect T1 values.
Currently there is no reference standard for measuring
myocardial T1 in vivo [32], and the extent of the effect
of blood T1 on myocardial T1 is unknown. Furthermore,
myocardial T1 values have been found to differ over the
cardiac cycle, and this can be attributed to myocardial
contraction compressing the vasculature [33] with re-
duced native myocardial T1 values during systole due to
less blood (with longer T1) present in the myocardium
[12]. Systolic readout has been proposed to reduce myo-
cardial T1 variability by reducing partial volume effects
since the myocardium is thicker in systole, and could theor-
etically include less intramyocardial blood [22, 34, 35].
Notably, in our data myocardial T1 values did not vary with
end-diastolic myocardial thickness, but did vary with
hematocrit. This suggests that measuring the native myo-
cardial T1 values in a conservatively placed ROI in the mid-
mural third of the septum in a clinical population reduces
contamination from the blood pool. However, the results
are surprising, considering that hematocrit did not inde-
pendently contribute to native myocardial T1 values in the
multivariate regression analysis. Hematocrit is not the only
factor contributing to blood T1, and therefore the T1 of the
blood is a better correction measure to use for native myo-
cardial T1. Previous studies have assumed linear relation-
ships between myocardial T1 values and blood T1 [22, 36].
In this study, we chose to correct for blood R1 and R1*. R1
is linearly related to the concentration of differing T1 spe-
cies such as a contrast agent or blood, as opposed to T1.
However, there could potentially be other relationships be-
tween native myocardial T1 values and other correction
factors. This highlights the complexity of T1 mapping, but
also stresses the importance of post-processing methods to
increase precision and enhance clinical diagnostic use. To
make the blood correction method clinically applicable we
chose to correct for hematocrit, as this is determined prior
to imaging in our clinical routine, for the purpose of
performing extracellular volume fraction (ECV) mapping.
Other parameters that could have been considered are fer-
ritin or hepcidin. However, this was not performed in the
current study. Furthermore, the blood in the RV is less oxy-
genated than in the LV, and therefore more paramagnetic
than in the LV [18]. As the LV myocardium is directly
perfused by the coronary arteries from the aorta, the use of
mean blood T1 and T1* could potentially degrade the
blood correction model. However, mean T1 and T1* values
were chosen in order to make blood correction feasible by
implementing an automatic (LV and RV) blood pool mask
[27] for inline reconstruction of a blood corrected T1 map.
Furthermore, Reiter et al. [22] showed that sex differ-
ences in normal T1 values can be eliminated by blood
correction. We also showed that sex differences were
eliminated by blood correction in the derivation cohort,
and in healthy volunteers. However, the sex differences
in the validation cohort were reduced, but not elimi-
nated following blood correction. This could be due to
different distributions of physiological factors in different
populations such as age, hematocrit, and oxygen pressure,
as the means of these factors did not differ between the
males or females in the validation and derivation cohorts
in this study. This shows that blood correction provides
improved precision in native myocardial T1, but not to
the extent that it completely eliminates sex differences in
clinical patients, even though the remaining difference
had a very small magnitude. Further studies may be of
value to better understand these mechanisms.
MOLLI sequences and myocardial T1 variability
Several different methods to quantitatively measure T1 re-
laxation times are currently in clinical use [37]. The original
MOLLI pulse sequence with acquisition over 17 successive
heart beats has become a commonly used T1 mapping
method [1]. The original MOLLI sequence has high preci-
sion, however the accuracy declines with longer T1 values,
and is particularly susceptible to higher heart rates [38].
Variations of MOLLI have been purposed to reduce
breath-hold duration, and reduce heart rate sensitivity
such as the 5(3s)3 [30, 39] scheme. The 5(3s)3 protocol has
high precision, but somewhat limited accuracy for shorter
T1 values [38]. The Shortened MOLLI (ShMOLLI) scheme
consists of sequential inversion-recovery acquisitions of nine
successive heart beats [29] and uses a conditional fitting algo-
rithm to account for the short recovery period between in-
version pulses. The conditional fitting discards data,
sacrificing precision without improving accuracy [38]. T1
mapping can also be performed with saturation recovery
single-shot acquisition (SASHA) [40] which mitigates
the underestimation of T1 values by MOLLI, however
with a reduced precision [38]. SASHA was modified to
mitigate heart rate dependency with saturation pulse
prepared heart-rate-independent inversion recovery
(SAPPHIRE) [41], however, this approach still has a
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lower precision in measuring myocardial T1 compared
to MOLLI [42]. The myocardial T1 values in the pa-
tients in our study were 1023 ± 42.6 ms and 1030 ±
45.2 ms, which closely corresponds to the myocardial
T1 found in the healthy volunteers in our study (1027 ±
37 ms), both acquired using a MOLLI sequence. However,
this is longer and more variable than 962 ± 25 ms in healthy
volunteers imaged with ShMOLLI [10]. The mean differ-
ences in T1 are related to the inherent differences between
the sequences, and the differences in variability are likely
related to differences in ROI placement strategy. Further-
more, the blood correction model did not decrease myocar-
dial T1 variability in healthy volunteers, however it did
eliminate gender differences. This is probably due to fact
that healthy volunteers have a greater homogeneity in myo-
cardial T1 values, but also blood T1 values. It is possible
that the resultant blood correction reduction, even in a
study powered to reduce variability in healthy volunteers,
would be so small that it’s not clinically relevant. Therefore,
the necessary study design to illustrate the clinical perform-
ance of blood correction in native T1 mapping is to study
patients with variable T1 in both blood and myocardium.
Furthermore, T1 values differ over CMR magnetic field
strength, both for blood and myocardium. Blood correc-
tion assuming linear correlation has been performed
successfully at 3 T, however the changes in variability fol-
lowing blood correction were not evaluated [36]. There-
fore, blood correction is feasible for 3 T as well, however
the optimal correction model would have to be evaluated
in dedicated clinical cohorts and healthy volunteers.
Clinical implications
The proposed validated blood correction method might
have clinical significance for diseases that are character-
ized by a change in native myocardial T1 values, such as
amyloidosis, iron-overload cardiomyopathy, Anderson-
Fabry disease and other non-ischemic heart diseases.
With increased diagnostic precision, these diseases could
potentially be identified earlier when only subtle differ-
ences in the myocardial T1 may be present. The range
of myocardial T1 values was decreased by 25% in the
derivation cohort. This suggests that blood correction
helps in determining the true biological variability in
myocardial T1 values, making it easier to differentiate
pathological myocardial T1 values from normal myocar-
dial T1 values. Native T1 mapping has shown diagnostic
promise in amyloidosis [5, 43], as native myocardial T1
increases with amyloid deposition and inflammation
[44]. Amyloidosis can be apparent in late gadolinium
enhancement (LGE) images, but the patterns are often
diffuse and globally distributed [45]. This can pose a
challenge when selecting the inversion time for LGE im-
aging, since normal myocardium may be absent. How-
ever, native T1 mapping is not dependent upon normal
myocardium for determining normality, and can there-
fore provide a useful imaging method in amyloidosis.
Furthermore, native myocardial T1 mapping has been
shown to be an independent predictor of survival in
amyloidosis [46]. By correcting for myocardial blood
content, the differences between normal and diseased
myocardium might increase and allow for earlier clinical
detection of disease.
Anderson-Fabry is a disease with accumulation of glyco-
sphingolipids within lysosomes, causing progressive fibro-
sis in certain tissues [47]. Native T1 mapping has shown
promising results for identifying these patients since
native myocardial T1 decreases, and might be used as a
surrogate measure for the disease [7]. With less variability
in native myocardial T1 values following blood correction,
diagnostic precision increases. Therefore, the diagnostic
accuracy provided by native T1 mapping of cardiac in-
volvement by Anderson-Fabry disease may improve.
Furthermore, differences in myocardial T1 values at
RV insertion points between patients with and without
pulmonary hypertension (PH) were highlighted by blood
correction [36], suggesting that blood correction can in-
crease diagnostic precision for diseases with more subtle
changes in native myocardial T1.
Limitations
This study included patients with known or suspected
heart disease to develop and validate a blood correction
method. Patients were used in order to yield the clinical
ranges of myocardial and blood T1 values necessary for
determining meaningful correlations. As patients were
used, this also sometimes resulted in changes in the
MOLLI acquisition parameters with varying FoV size and
phase encoding lines, which can influence the accuracy of
the T1 measurement. However, the strategy used under-
scores that the resulting blood correction model is valid
for clinical use, since adjusting image acquisition parame-
ters is a part of the clinical routine. Furthermore, only sep-
tal myocardial T1 values were acquired, and not all
segments according to American Heart Association
(AHA) segmentation scheme, which has been used in
other studies [36, 48]. Notably, it is not known how the
blood correction model in this study affects the rest of the
myocardium. However, Reiter et al. [22] studied all seg-
ments of the left ventricle and identified negligible differ-
ences in myocardial T1 throughout the left ventricle. This
suggests that the same blood correction could be applied
for the entire left ventricular myocardium.
Conclusions
Blood correction improves the precision of native myo-
cardial T1 measurement by 13% and reduces gender dif-
ferences. Image-based correction of native myocardial
T1 values for R1 and R1* of blood is valid for clinical
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use and may improve disease detection in the clinical
evaluation of native myocardial T1, and reduce sample
size needs for clinical research.
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